IN2015DN00438A - - Google Patents

Info

Publication number
IN2015DN00438A
IN2015DN00438A IN438DEN2015A IN2015DN00438A IN 2015DN00438 A IN2015DN00438 A IN 2015DN00438A IN 438DEN2015 A IN438DEN2015 A IN 438DEN2015A IN 2015DN00438 A IN2015DN00438 A IN 2015DN00438A
Authority
IN
India
Prior art keywords
periodontitis
present disclosure
diseases associated
describes methods
screening
Prior art date
Application number
Inventor
John D Lambris
George Hajishengallis
Original Assignee
Univ Pennsylvania
Univ Louisville Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Univ Louisville Res Found filed Critical Univ Pennsylvania
Publication of IN2015DN00438A publication Critical patent/IN2015DN00438A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)

Abstract

The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.
IN438DEN2015 2012-06-20 2013-06-19 IN2015DN00438A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662022P 2012-06-20 2012-06-20
US13/801,096 US9579360B2 (en) 2012-06-20 2013-03-13 Methods of treating or preventing periodontitis and diseases associated with periodontitis
PCT/US2013/046599 WO2013192319A1 (en) 2012-06-20 2013-06-19 Methods of treating or preventing periodontitis and diseases associated with periodontitis

Publications (1)

Publication Number Publication Date
IN2015DN00438A true IN2015DN00438A (en) 2015-06-19

Family

ID=49769337

Family Applications (1)

Application Number Title Priority Date Filing Date
IN438DEN2015 IN2015DN00438A (en) 2012-06-20 2013-06-19

Country Status (8)

Country Link
US (2) US9579360B2 (en)
EP (1) EP2863949B1 (en)
JP (1) JP6363595B2 (en)
CN (1) CN104640567A (en)
AU (1) AU2013277217B2 (en)
CA (1) CA2877299C (en)
IN (1) IN2015DN00438A (en)
WO (1) WO2013192319A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987725B (en) 2011-09-07 2019-04-16 宾夕法尼亚州大学理事会 Compstatin analogs with improved pharmacokinetic properties
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
CN106456605A (en) 2014-02-25 2017-02-22 艾其林医药公司 Amino compounds for treatment of complement mediated disorders
AP2016009612A0 (en) 2014-06-12 2016-12-31 Ra Pharmaceuticals Inc Modulation of complement activity
HUE056613T2 (en) 2015-01-28 2022-02-28 Ra Pharmaceuticals Inc Modulators of complement activity
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
KR20180094913A (en) 2015-12-16 2018-08-24 라 파마슈티컬스 인코포레이티드 Regulator of complement activity
MX2019006527A (en) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Modulators of complement activity.
EP3985002B1 (en) 2017-03-01 2025-05-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2019028284A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
JP2021505565A (en) 2017-12-04 2021-02-18 ラ ファーマシューティカルズ インコーポレイテッドＲａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Modulator of complement activity
JP2021507884A (en) * 2017-12-15 2021-02-25 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Administration regimen and related compositions and methods
AU2019247467B2 (en) 2018-04-06 2023-01-19 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
JP7443375B2 (en) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド Macrocyclic compounds for the treatment of medical disorders
KR20210093855A (en) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 Conformational forms of complement factor D inhibitors
JP7471300B2 (en) 2018-12-17 2024-04-19 アキリオン ファーマシューティカルズ， インコーポレーテッド Targeted dosing for treating complement-mediated diseases
JP2022524078A (en) 2019-03-08 2022-04-27 ラ ファーマシューティカルズ インコーポレイテッド Zircoplan as a deep tissue penetrating C5 inhibitor
US20230115176A1 (en) 2019-03-29 2023-04-13 Ra Pharmaceuticals, Inc. Complement Modulators and Related Methods
AU2020261059A1 (en) 2019-04-24 2021-10-14 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270365A (en) 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
JP2001294536A (en) * 2000-04-12 2001-10-23 Sunstar Inc Prophylactic/therapeutic preparation for periodontal disease
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
ES2600460T3 (en) * 2005-05-10 2017-02-09 Intermune, Inc. Pyridone-2-one derivatives as modulators of the stress-activated protein kinase system
DK2148691T3 (en) * 2007-02-05 2015-08-17 Apellis Pharmaceuticals Inc Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
PL2424557T3 (en) * 2009-05-01 2018-04-30 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and c-terminal modifications
WO2010132954A1 (en) 2009-05-21 2010-11-25 Oral Health Australia Pty Ltd Method of treating periodontal disease by administering antagonists of par-2
JP5675821B2 (en) * 2009-09-23 2015-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート TOLL-like receptor modulator and use thereof
WO2011091366A2 (en) 2010-01-22 2011-07-28 University Of Louisville Research Foundation, Inc. Methods of treating or preventing periodontitis and diseases associated with periodontitis
EP2548888B1 (en) * 2010-03-17 2017-11-01 Kagoshima University Periodontal-disease-specific peptide, and treatment and diagnosis of periodontal disease using same
CA2840270C (en) * 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
CN103987725B (en) * 2011-09-07 2019-04-16 宾夕法尼亚州大学理事会 Compstatin analogs with improved pharmacokinetic properties
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis

Also Published As

Publication number Publication date
US20130344082A1 (en) 2013-12-26
WO2013192319A1 (en) 2013-12-27
CA2877299C (en) 2022-07-12
AU2013277217B2 (en) 2018-03-08
JP6363595B2 (en) 2018-07-25
EP2863949A1 (en) 2015-04-29
US9579360B2 (en) 2017-02-28
AU2013277217A2 (en) 2015-01-22
US20170202935A1 (en) 2017-07-20
CA2877299A1 (en) 2013-12-27
JP2015523999A (en) 2015-08-20
AU2013277217A1 (en) 2015-01-22
EP2863949A4 (en) 2016-03-02
US10668135B2 (en) 2020-06-02
CN104640567A (en) 2015-05-20
EP2863949B1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
IN2015DN00438A (en)
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
PH12016502167A1 (en) Hdl theraphy markers
MX2016004927A (en) Compositions useful for treating disorders related to kit.
EA201690007A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
GB201103062D0 (en) Method
MX2014010481A (en) New compositions for treating amyotrophic lateral sclerosis.
JOP20140141B1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
MX2021011946A (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency.
IN2014DN06792A (en)
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
PL3082831T3 (en) Compositions comprising methyl-cyclodextrines to treat or prevent diseases by enhancement of the hdl-cholesterol level
MX2020002544A (en) Glycopyrrolate salts.
EP3065768A4 (en) Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
MX2016005760A (en) Gsk-3 inhibitors.
MX2018000715A (en) Methods for treating cancer using apilimod.
PL2792364T3 (en) Composition for preventing or treating hangover
MX2015007518A (en) Methods for treating pruritus.
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX2016004540A (en) Thiazolopyrimidinones as modulators of nmda receptor activity.
MX348040B (en) Hedgehog antagonists having zinc binding moieties.
MX2016006975A (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases.
MX2020009966A (en) Dosage forms and therapeutic uses l-4-chlorokynurenine.
IN2014DN06738A (en)